{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:18:46Z","timestamp":1776241126442,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T00:00:00Z","timestamp":1525478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AA022489"],"award-info":[{"award-number":["U01 AA022489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Conatus Pharmaceuticals Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00109-018-1642-9","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T02:01:21Z","timestamp":1525485681000},"page":"575-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation"],"prefix":"10.1007","volume":"96","author":[{"given":"Akiko","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Wree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Povero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kneiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al","family":"Spada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel E.","family":"Feldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,5]]},"reference":[{"key":"1642_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5009\/gnl15593","volume":"10","author":"SB Ho","year":"2016","unstructured":"Ho SB, Matheny ME, Schnabl BE (2016) Changes in hospital admissions and mortality for complications of cirrhosis: implications for clinicians and health systems. Gut Liver 10:8\u20139","journal-title":"Gut Liver"},{"key":"1642_CR2","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/hep.28771","volume":"64","author":"W Laleman","year":"2016","unstructured":"Laleman W, Trebicka J, Verbeke L (2016) Evolving insights in the pathophysiology of complications of cirrhosis: the farnesoid X receptor (FXR) to the rescue? Hepatology 64:1792\u20131794","journal-title":"Hepatology"},{"key":"1642_CR3","doi-asserted-by":"publisher","DOI":"10.3402\/jev.v4.27066","volume":"4","author":"M Yanez-Mo","year":"2015","unstructured":"Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borras FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J et al (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4:27066. \n                    https:\/\/doi.org\/10.3402\/jev.v4.27066","journal-title":"J Extracell Vesicles"},{"key":"1642_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/hep.28838","volume":"65","author":"A Eguchi","year":"2017","unstructured":"Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Starkel P, Schnabl B, Ohno-Machado L et al (2017) Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology 65:475\u2013490","journal-title":"Hepatology"},{"key":"1642_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jhep.2015.11.020","volume":"64","author":"VK Verma","year":"2016","unstructured":"Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, Cao S, Contreras PC, Malhi H, Kamath PS, Gores GJ, Shah VH (2016) Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol 64:651\u2013660","journal-title":"J Hepatol"},{"key":"1642_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.gastro.2012.03.040","volume":"143","author":"PE Rautou","year":"2012","unstructured":"Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, Devue C, Heymes C, Letteron P, Elkrief L et al (2012) Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology 143:166\u2013176 e166","journal-title":"Gastroenterology"},{"key":"1642_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1124\/jpet.103.060129","volume":"308","author":"A Canbay","year":"2004","unstructured":"Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ (2004) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308:1191\u20131196","journal-title":"J Pharmacol Exp Ther"},{"key":"1642_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/liv.12570","volume":"35","author":"FJ Barreyro","year":"2015","unstructured":"Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, Carreras MC, Poderoso JJ, Gores GJ (2015) The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int : Off J Int Assoc Study Liver 35:953\u2013966","journal-title":"Liver Int : Off J Int Assoc Study Liver"},{"key":"1642_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.23167","volume":"50","author":"RP Witek","year":"2009","unstructured":"Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM, Omenetti A, Jung Y, Teaberry V, Choi SS, Guy CD, Pollard J, Charlton P, Diehl AM (2009) Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50:1421\u20131430","journal-title":"Hepatology"},{"key":"1642_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jhep.2010.03.016","volume":"53","author":"QM Anstee","year":"2010","unstructured":"Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, Thomas HC, Thursz MR, Goldin RD (2010) Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J Hepatol 53:542\u2013550","journal-title":"J Hepatol"},{"key":"1642_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmgh.2014.11.005","volume":"1","author":"P Hirsova","year":"2015","unstructured":"Hirsova P, Gores GJ (2015) Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol 1:17\u201327","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1642_CR12","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1600-6143.2006.01595.x","volume":"7","author":"ES Baskin-Bey","year":"2007","unstructured":"Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK et al (2007) Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 7:218\u2013225","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"1642_CR13","doi-asserted-by":"crossref","unstructured":"Eguchi A, De Mollerat Du Jeu X, Johnson CD, Nektaria A, Feldstein AE (2016) Liver bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J Hepatol 64: 699\u2013707. DOI","DOI":"10.1016\/j.jhep.2015.11.002"},{"key":"1642_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2014.03.028","volume":"61","author":"M Lazic","year":"2014","unstructured":"Lazic M, Eguchi A, Berk MP, Povero D, Papouchado B, Mulya A, Johnson CD, Feldstein AE (2014) Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice. J Hepatol 61:107\u2013115","journal-title":"J Hepatol"},{"key":"1642_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17474124.2017.1300060","volume":"11","author":"BL Woolbright","year":"2017","unstructured":"Woolbright BL, Ding WX, Jaeschke H (2017) Caspase inhibitors for the treatment of liver disease: friend or foe? Expert Rev Gastroenterol Hepatol 11:397\u2013399","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1642_CR16","first-page":"47","volume":"7","author":"P Wang","year":"2016","unstructured":"Wang P, Koyama Y, Liu X, Xu J, Ma HY, Liang S, Kim IH, Brenner DA, Kisseleva T (2016) Promising therapy candidates for liver fibrosis. Front Physiol 7:47","journal-title":"Front Physiol"},{"key":"1642_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123110","volume":"10","author":"A Eguchi","year":"2015","unstructured":"Eguchi A, Mulya A, Lazic M, Radhakrishnan D, Berk MP, Povero D, Gornicka A, Feldstein AE (2015) Microparticles release by adipocytes act as \u201cfind-me\u201d signals to promote macrophage migration. PLoS One 10:e0123110. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0123110","journal-title":"PLoS One"},{"key":"1642_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113651","volume":"9","author":"D Povero","year":"2014","unstructured":"Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE (2014) Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One 9:e113651. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0113651","journal-title":"PLoS One"},{"key":"1642_CR19","doi-asserted-by":"crossref","unstructured":"Povero D, Eguchi A, Niesman IR, Andronikou N, de Mollerat du Jeu X, Mulya A, Berk M, Lazic M, Thapaliya S, Parola M, et al. (2013) Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal 6: ra88. DOI","DOI":"10.1126\/scisignal.2004512"},{"key":"1642_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","volume":"150","author":"P Hirsova","year":"2016","unstructured":"Hirsova P, Ibrahim SH, Krishnan A, Verma VK, Bronk SF, Werneburg NW, Charlton MR, Shah VH, Malhi H, Gores GJ (2016) Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes. Gastroenterology 150:956\u2013967","journal-title":"Gastroenterology"},{"key":"1642_CR21","unstructured":"Garcia-Tsao G, Fuchs M, Shiffman ML, Chan JL, Morris M, Yamashita M, Spada AP, Hagerty D, Bosch J Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology 62: 1382A"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-018-1642-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-018-1642-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T16:45:14Z","timestamp":1589561114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-018-1642-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,5]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1642"],"URL":"https:\/\/doi.org\/10.1007\/s00109-018-1642-9","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,5]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors state no conflict of interest, except Al Spada and Patricia Contreras who are employees of Conatus Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}